| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Improvement of the dissolution rate and enhancement of the solubility of drugs is required to improve the bioavailability of poorly water-soluble drugs. We focused on co-amorphous formulations that contain a poorly soluble drug and a low molecular-weight compound to improve solubility and stability. In the present study, a co-amorphous model drug was prepared by spray-drying of probucol (PC) and atorvastatin calcium trihydrate salt (ATO) as lower water solubility and co-former components, respectively. The co-amorphization of PC and ATO prepared can be stored for 35 days without crystallization and improve the solubility of PC in water. Furthermore, we prepared three-component amorphous formulations with several kinds of poorly water-soluble model drugs and obtained useful knowledge about the relationship between formulations and solubility improvement of the drugs.
|
